ArticleAAPS PharmSciTech2026
Self-emulsifying Delivery System for Improving Biopharmaceutical Performance of a Novel Antitubercular Agent: Formulation Development, Biological Activity and Pharmacokinetic Evaluation.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A nitroimidazole-derived lead (IIIM-019) was developed as a part of our institutional drug discovery program in the area of tuberculosis. This molecule suffers from poor aqueous solubility and to overcome this limitation, lipid-based self-emulsifying drug delivery system (SEDDS) was developed. The SEDDS was characterized for emulsification efficiency, droplet size, stability and drug release. The morphology of SEDDS was investigated by transmission electron microscopy (TEM). The cellular uptake of formulation was assessed in Caco-2 cells and anti-tubercular activity was evaluated in M. tuberculosis H37Rv. Further, the pharmacokinetic profile of formulation was investigated in Balb/C mice. The optimal formulation, F2, was selected based on clarity, particle size, and stability. Characterization studies confirmed that F2 possessed favorable attributes, including a particle size of 120.6 ± 0.7 nm, and thermodynamic stability. The dissolution study revealed significantly enhanced release profile of IIIM-019 from SEDDS compared to its native form. The developed formulation showed uptake in Caco-2 cells and it also exhibited significantly improved anti-tubercular activity. Further, pharmacokinetic study indicated higher plasma exposure and decreased clearance than unformulated IIIM-019. The developed SEDDS formulation increased solubility, dissolution, plasma exposure, and therapeutic effectiveness of IIIM-019, representing a promising carrier for oral administration of investigated anti-tubercular lead.
Indexed as
Identifiers
42717120What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.